Larvol Delta - BioAge-Labs-Announces-First-Participant-Dosed-in-QUELLDME-a-Phase-2-Trial-of-BGE102-a-Novel-Oral-NLRP3-Inhibitor-in-Diabetic-Macular-Edema

BGE-102 - BioAge Labs

https://www.globenewswire.com/news-release/2026/09/08/3357592/0/en/bioage-labs-announces-first-participant-dosed-in-quell-dme-a-phase-2-trial-of-bge-102-a-novel-oral-nlrp3-inhibitor-in-diabetic-macular-edema.html

Sep 8, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next